27
KIT
Type 2 too?
INTRO: Can CGM help prevent - as well as improve
the control of - Type 2 diabetes?
Type 2 diabetes continues
to rise - of the 4.6m people
living with diabetes in
the UK, 90% have Type 2.
Additionally, it is estimated nearly
1.3m people could be living with it
and are yet to be diagnosed.
From 26 May to 1 June Diabetes
UK and the NHS ran a Type 2
Prevention Week, the theme of
which shifting away from personal
responsibility towards systemic,
environmental, and policy-driven
barriers to not only help those with
Type 2 now, but also help prevent it
in the future.
Dexcom, supplier of a range
of continuous glucose monitor
solutions (CGMs) takes the view
that that a major barrier for Type
2 is lack of awareness and access
to Monitoring (CGM - as you're
likely aware, this is crucial diabetes
technology that tracks glucose
levels in real-time, helping people to
manage their condition and reduce
complications, as well as time in
hospital.
More effective?
New data from Dexcom's State of
Type 2 Report - which looked at
the opinions of HCPs and as well as
people living with diabetes in the UK
and some key European countries -
found that HCPs believe CGM should
be the standard of care for Type 2,
and a preferred treatment to just
using medications.
Key UK report findings include:
• 53% of UK HCPs believe better
access to CGM has the potential
to positively help Type 2 patients
manage their condition in the next
10 years, vs. 35% who said more
effective medications
• A majority of UK HCPs believe CGM
should be the standard of care for
people with Type 2 using the below
treatments / therapies:
• 95% on multiple daily insulin
injections
• 89% on basal injections
• 45% on oral medications
• 35% on lifestyle interventions
• 72% of those living with Type 2
diabetes believe that using a CGM
device helps to improve their
lives, a further 74% believe that
it would also reduce the risk of
complications.
• The report also reveals that despite
growing clinical support for CGM,
there is significant room for growth
in terms of early education and
access for this diabetes technology.
Extending access
Shay Speakman Brown, Head of
Market Access for Dexcom UK, says,
"We're seeing a clear shift in how
Type 2 diabetes is being managed
in the UK, with the majority of
healthcare professionals now viewing
Continuous Glucose Monitoring
(CGM) as the impending standard of
care for those living with Type 2 and
using insulin. Dexcom ONE+ is now
available on the NHS and as access
continues to grow, we're entering
a pivotal moment as systems begin
to align with clinical best practice.
Technology such as Dexcom ONE+
can play a key role in bettering health
equity and improving the long-term
outcomes for people living with Type
2 diabetes."
www.dexcom.uk